Filtered By:
Condition: Pain
Procedure: Angioplasty

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 35 results found since Jan 2013.

Optimal medical therapy for coronary artery disease in 2011 - perspectives from the STICH Trial.
Authors: Whayne TF, Saha SP, Quevedo K, Mukherjee D Abstract Medical, percutaneous interventional, and surgical treatments for the management of coronary heart disease have progressed markedly during the past decade. There is evidence to suggest that for patients with stable coronary heart disease optimal medical therapy is equal in effectiveness for lowering the risk of major cardiovascular events, such as cardiovascular death, myocardial infarction, and stroke, as are revascularization procedures, such as coronary artery bypass grafting or percutaneous coronary intervention. The landmark Surgical Treatment for Is...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - November 23, 2014 Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research

Supplemental oxygen in patients without hypoxia in ST segment elevation myocardial infarction increases myocardial injury and infarct size
Commentary on: Stub D, Smith K, Bernard S, et al.. AVOID Investigators. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation 2015;131:2143–50. Context In patients with ST segment elevation myocardial infarction (STEMI), timely reperfusion, best obtained with primary percutaneous coronary intervention (pPCI), is a mainstay to reduce infarct size (IS) and improve clinical outcome. Routine oxygen administration in normoxic patients with STEMI before pPCI, while mentioned by international guidelines,1 is not supported by randomised evidence. Stub and colleagues performed the AVOID study to compare...
Source: Evidence-Based Medicine - January 22, 2016 Category: Internal Medicine Authors: Crimi, G. Tags: Clinical trials (epidemiology), Drugs: cardiovascular system, Pain (neurology), Stroke, Interventional cardiology, Ischaemic heart disease, Drugs: respiratory system Therapeutics/Prevention Source Type: research

0417 : Thrombolisis with tenecteplase (metalyse) in myocardial infarction an always topical issue
Conclusion Thrombolysis by Tenecteplase of STEMI admitted to ICCU was successfull in 89% of cases, which proves its effectiveness compared with other thrombolytic agents. The reperfusion rate was inversely proportional to time limit chest pain – arrival at ER. Patient education to call the ambulance (190) in case of chest pain should improve this delay and increase the reperfusion rate. The author hereby declares no conflict of interest
Source: Archives of Cardiovascular Diseases Supplements - June 15, 2016 Category: Cardiology Source Type: research

Epidemiological characteristics, management and early outcomes of acute coronary syndromes in Greece: The PHAETHON study.
CONCLUSIONS: The PHAETHON study provided valuable insights into the epidemiology, management and outcome of ACS patients in Greece. Management of ACS resembles the management observed in other European countries. However, several issues still to be addressed by public authorities for the timely and proper management of ACS. PMID: 27451914 [PubMed - as supplied by publisher]
Source: Hellenic Journal of Cardiology - July 29, 2016 Category: Cardiology Tags: Hellenic J Cardiol Source Type: research

11-dehydro thromboxane B2 levels after percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease during a one year follow-up period.
In this study, 175 patients diagnosed with peripheral arterial occlusive disease (PAOD) and demonstrating short-distance claudication or ischemic rest pain, requiring PTA in either the iliac, femoral, or popliteal arteries, were enrolled. The excretion of 11-dehydro thromboxane B2 (TXB2) was measured in urine samples by high-performance liquid chromatography-mass spectrometry and recalculated based on the creatinine concentration. The urine samples were collected the morning prior to PTA, immediately following PTA and the day after PTA. All of the study subjects were then observed for a period of 12 months. Urine samples w...
Source: J Physiol Pharmacol - May 31, 2016 Category: Drugs & Pharmacology Authors: Maga P, Sanak M, Jawien J, Rewerska B, Maga M, Wachsmann A, Koziej M, Gregorczyk-Maga I, Nizankowski R Tags: J Physiol Pharmacol Source Type: research

A simple risk score in acute ST-elevation myocardial infarction: Modified ACEF(age, creatinine, and ejection fraction) score.
CONCLUSION: The modified ACEF score is a predictor of cardiac mortality and morbidity during 1-year follow-up. PMID: 28081310 [PubMed - in process]
Source: Turkish Journal of Medical Sciences - January 14, 2017 Category: Journals (General) Tags: Turk J Med Sci Source Type: research

Discovery of Leonuri and therapeutical applications: From bench to bedside
Publication date: Available online 9 March 2018 Source:Pharmacology & Therapeutics Author(s): Yi Zhun Zhu, Weijun Wu, Qing Zhu, Xinhua Liu Despite several advances in percutaneous coronary intervention and the discovery of new drugs, the incidence of myocardial infarction and deaths due to cardiovascular diseases (CVD) has not decreased markedly in China. The quality of life is affected seriously, which further results in great social and family burden. Many drugs, from the century-old aspirin to the newly FDA-approved Byvalson, have been proven to be effective in the treatment and prevention of CVD. As clinically...
Source: Pharmacology and Therapeutics - March 9, 2018 Category: Drugs & Pharmacology Source Type: research

Safety and feasibility of returning patients immediately to their originating hospitals after primary percutaneous coronary intervention
ConclusionThe immediate return of low risk STEMI patients to their originating hospitals after PPCI is safe and feasible and is effective strategy to provide this prefer and effective re-perfusion therapy to vast majority of patients with STEMI.
Source: Journal of the Saudi Heart Association - October 5, 2018 Category: Cardiology Source Type: research

Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine
ConclusionsMorphine-treatment was associated with increased GP IIb/IIIa inhibitor use, less pre-PCI TIMI 3 flow, and more bleeding. Judicious morphine use is advised with non-opioid analgesics preferred for non-severe acute pain.Trial Registrationclinicaltrials.gov identifier: NCT01347580.
Source: American Journal of Cardiovascular Drugs - October 23, 2018 Category: Cardiology Source Type: research

12 Innovations That Will Change Health Care and Medicine in the 2020s
Pocket-size ultrasound devices that cost 50 times less than the machines in hospitals (and connect to your phone). Virtual reality that speeds healing in rehab. Artificial intelligence that’s better than medical experts at spotting lung tumors. These are just some of the innovations now transforming medicine at a remarkable pace. No one can predict the future, but it can at least be glimpsed in the dozen inventions and concepts below. Like the people behind them, they stand at the vanguard of health care. Neither exhaustive nor exclusive, the list is, rather, representative of the recasting of public health and medic...
Source: TIME: Health - October 25, 2019 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized HealthSummit19 technology Source Type: news

Cardiovascular Biology of Prostanoids and Drug Discovery.
Abstract Prostanoids are a group of bioactive lipids that are synthesized de novo from membrane phospholipid-released arachidonic acid and have diverse functions in normal physiology and disease. NSAIDs, which are among the most commonly used medications, ameliorate pain, fever, and inflammation by inhibiting COX (cyclooxygenase), which is the rate-limiting enzyme in the biosynthetic cascade of prostanoids. The use of NSAIDs selective for COX-2 inhibition increases the risk of a thrombotic event (eg, myocardial infarction and stroke). All NSAIDs are associated with an increased risk of heart failure. Substantial v...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - April 15, 2020 Category: Cardiology Authors: Zhu L, Zhang Y, Guo Z, Wang M Tags: Arterioscler Thromb Vasc Biol Source Type: research

What Are the Main Acyanotic Congenital Heart Diseases?
Discussion Congenital heart diseases (CHD) are malformations of the heart and great vessels. It occurs in about 5-8/1000 live births. Cyanotic congenital heart disease is often noted perinatally because of cyanosis, respiratory distress and/or poor feeding or other distress type problems. A review can be found here. Acyanotic congenital heart disease (ACHD) can present at birth but often is seen in older children or adults unless the lesions are severe, especially obstructive lesions. Severe lesions may also cause cyanosis and distress type problems in patients also. Shunting lesions cause problems by diverting blood flo...
Source: PediatricEducation.org - August 17, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Safety and Efficacy of Perioperative Use of Evolocumab in Myocardial Infarction Patients: Study Protocol for a Multicentre Randomized Controlled Trial
This study aims to evaluate the safety and efficacy of this treatment regimen.MethodsA multicentre, prospective, randomized, controlled superiority trial will be conducted in 530 statin-na ïve MI patients. All eligible patients will be randomized to the evolocumab group (140 mg subcutaneously injected once before revascularization + 14 days after the first dose) or the control group (no evolocumab injection). Evolocumab will then be administered depending on the patient's lipid profile. Both groups will be treated simultaneously with standardized secondary preventive medications. The primary end points are major adv...
Source: Advances in Therapy - February 27, 2021 Category: Drugs & Pharmacology Source Type: research